Aims and scope
The fundamental and interdependent processes responsible for cancer initiation, tumor progression, and the response to treatment pose challenges that call for multidisciplinary efforts. It is increasingly recognized that no single scientific discipline currently possesses the experimental and conceptual tools needed to address all components of this exceedingly complex and heterogeneous disease process. Cancer Convergence creates a single platform to bring together techniques and synergistic perspectives from different disciplines to facilitate the study and development of strategies for curing cancer. This new journal connects researchers from the physical and mathematical sciences and engineering, who bring quantitative approaches, new questions, and testable hypotheses to the study of cancer, with cancer biologists and research oncologists who represent a long tradition of progress toward understanding the emergence and pathogenesis of the disease. As a platform for collaboration, Cancer Convergence welcomes both qualitative and quantitative approaches that offer new insight into the etiology, mechanisms, diagnosis, or treatment of cancer.
Multifaceted physical, chemical, and biological processes maintain homeostasis in animals, and failure of this intricate process often leads to the development of cancer. Therefore, Cancer Convergence welcomes papers from researchers interested in tissue, organ, and systems maintenance where disruption may be a causal agent of cancer. Overall, the journal aims at understanding the principles that operate during normal function of a complex animal body and their relationship to the cancer processes that govern failure at the cellular, tissue, organ, and systems level. While significant advances have been made in cancer research and treatment, a more interdisciplinary approach is needed to achieve a comprehensive understanding of the disease leading to improved diagnostic and treatment strategies.
Why publish your article in Cancer Convergence
Cancer Convergence's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Cancer Convergence offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Cancer Convergence gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Cancer Convergence are included in article alerts and regular email updates. Some may be highlighted on Cancer Convergence’s pages and on the BioMed Central homepage.
In addition, articles published in Cancer Convergence may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Cancer Convergence. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Cancer Convergence you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.
All articles published by Cancer Convergence are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Cancer Convergence you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Cancer Convergence therefore levies an article-processing charge of £940.00/$1475.00/€1200.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BMC on SpringerLink. We are working closely with relevant indexing services including PubMed Central and Web of Science (Clarivate Analytics) to ensure that articles published in Cancer Convergence will be available in their databases when appropriate.
Citing articles in Cancer Convergence
Articles in Cancer Convergence should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Cancer Converg [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Cancer Converg 2009, 1:115.
1:115 refers to article 115 from Volume 1 of the journal.
All manuscripts submitted to Cancer Convergence should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.